Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.94 is 29% below its 4-year average of -2.28, near the low end of its 4-year range (-3.64–-1.02).
15.64% above its 12-month average of -3.49.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.63.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 11 comparable quarters.
EARNINGS PER SHARE (EPS)
-2.94
EARNINGS PER SHARE (EPS) AVG TTM
-3.49
EARNINGS PER SHARE (EPS) AVG 3Y
-2.70
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+15.64%
CURRENT VS 3Y AVG
-9.02%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Kyverna Therapeutics, Inc.
Market Cap
$378.75M
Earnings Per Share (EPS)
-2.94
TTM Avg
-3.49
3Y Avg
-2.70
5Y Avg
N/A
Market Cap
$376.18M
Earnings Per Share (EPS)
-0.50
TTM Avg
-5.17
3Y Avg
-17.19
5Y Avg
-12.52
Market Cap
$389.14M
Earnings Per Share (EPS)
-5.18
TTM Avg
-2.77
3Y Avg
-1.90
5Y Avg
-1.90
Market Cap
$359.05M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.30
3Y Avg
-1.38
5Y Avg
-1.95
Market Cap
$398.49M
Earnings Per Share (EPS)
-3.33
TTM Avg
-2.70
3Y Avg
-1.54
5Y Avg
-2.91
Market Cap
$357.44M
Earnings Per Share (EPS)
-0.14
TTM Avg
-0.19
3Y Avg
-0.48
5Y Avg
-0.56
Market Cap
$357.37M
Earnings Per Share (EPS)
-2.41
TTM Avg
-4.66
3Y Avg
-5.40
5Y Avg
-4.56
Market Cap
$354.48M
Earnings Per Share (EPS)
1.48
TTM Avg
1.49
3Y Avg
2.03
5Y Avg
3.82
Market Cap
$342.72M
Earnings Per Share (EPS)
2.65
TTM Avg
-5.30
3Y Avg
-10.00
5Y Avg
-10.52
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | $378.75M | -2.94 | -3.49 | -2.70 | N/A |
| Canopy Growth Corporation (CGC)vs › | $376.18M | -0.50 | -5.17 | -17.19 | -12.52 |
| MapLight Therapeutics, Inc. (MPLT)vs › | $389.14M | -5.18 | -2.77 | -1.90 | -1.90 |
| Opus Genetics, Inc. (IRD)vs › | $359.05M | N/A | -1.30 | -1.38 | -1.95 |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $398.49M | -3.33 | -2.70 | -1.54 | -2.91 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $357.44M | -0.14 | -0.19 | -0.48 | -0.56 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.37M | -2.41 | -4.66 | -5.40 | -4.56 |
| Embecta Corp. (EMBC)vs › | $354.48M | 1.48 | 1.49 | 2.03 | 3.82 |
| Agenus Inc. (AGEN)vs › | $342.72M | 2.65 | -5.30 | -10.00 | -10.52 |
| Shoulder Innovations, Inc. (SI)vs › | $408.54M | -1.71 | -1.36 | -1.12 | -1.12 |
Trailing EPS (TTM)
$-2.94
Forward EPS (Est.)
$-2.76
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -3.64 |
| 2024-12-31 | -3.33 |
| 2022-12-31 | -1.12 |
| 2021-12-31 | -1.02 |
